Loyal founder and CEO Celine Halioua shares the story behind building the first company to develop FDA-approved drugs for canine lifespan extension, and why the hardest part wasn't the science.

Celine reflects on the early years of company building, when the most common reaction from investors and scientists alike was laughter. For nearly two years, the idea of a regulatory-approved longevity drug was treated as fringe. What changed wasn't the science. It was Loyal's willingness to do the work nobody else had done: constructing a regulatory path that gave the FDA something it could actually approve.

The discussion explores the insight at the core of Loyal's strategy. The obstacle to longevity drugs was never technological; it was structural. No one had designed a clinical trial rigorous enough to definitively prove lifespan extension, demonstrated the safety profile regulators required, or made a clear case for why extending a dog's life represented a positive outcome for both animal and owner. Loyal addressed all three, starting with large-breed dogs whose shorter lifespans make aging measurable and outcomes achievable within a reasonable trial window.

Celine also talks about the STAY study, Loyal's pivotal lifespan extension clinical trial, now enrolling 1,300 dogs across 70 veterinary clinics nationwide. The goal is to prove, to the highest regulatory standard, that dogs on Loyal's drug are statistically more likely to live longer, healthier lives than those on a placebo. It is, by design, the hard way. Durable impact, as Celine sees it, comes from solving the hard problems. Loyal hasn't done it any other way.

As Loyal moves toward potential commercial launch, Celine sees implications that extend well beyond veterinary medicine. Dogs co-evolve with humans, share our environments, and develop the same age-related diseases on a compressed timeline, making every aging dog a living model of human biology. If Loyal succeeds, it won't just add years to dogs' lives. It will normalize the idea of an aging drug in the public mind and force a simple, powerful question: if this works for my dog, why can't it work for my grandmother?